Inhibition of SARS-CoV-2 infection in human cardiomyocytes by targeting the Sigma-1 receptor disrupts cytoskeleton architecture and contractility

ABSTRACT
Heart dysfunction, represented by conditions such as myocarditis and arrhythmia, has been reported in COVID-19 patients. Therapeutic strategies focused on the cardiovascular system, however, remain scarce. The Sigma-1 receptor (S1R) has been recently proposed as a therapeutic target because its inhibition reduces SARS-CoV-2 replication. To investigate the role of S1R in SARS-CoV-2 infection in the heart, we used human cardiomyocytes derived from induced pluripotent stem cells (hiPSC-CM) as an experimental model. Here we show that the S1R antagonist NE-100 decreases SARS-CoV-2 infection and viral replication in hiPSC-CMs. Also, NE-100 reduces cytokine release and cell death associated with infection. Because S1R is involved in cardiac physiology, we investigated the effects of NE-100 in cardiomyocyte morphology and function. We show that NE-100 compromises cytoskeleton integrity and reduces beating frequency, causing contractile impairment. These results show that targeting S1R to challenge SARS-CoV-2 infection may be a useful therapeutic strategy but its detrimental effects in vivo on cardiac function should not be ignored.
Competing Interest Statement
The authors have declared no competing interest.
Subject Area
- Biochemistry (10298)
- Bioengineering (7614)
- Bioinformatics (26189)
- Biophysics (13445)
- Cancer Biology (10620)
- Cell Biology (15333)
- Clinical Trials (138)
- Developmental Biology (8452)
- Ecology (12753)
- Epidemiology (2067)
- Evolutionary Biology (16760)
- Genetics (11356)
- Genomics (15399)
- Immunology (10548)
- Microbiology (25040)
- Molecular Biology (10151)
- Neuroscience (54086)
- Paleontology (398)
- Pathology (1655)
- Pharmacology and Toxicology (2877)
- Physiology (4314)
- Plant Biology (9196)
- Synthetic Biology (2541)
- Systems Biology (6752)
- Zoology (1452)